According to the TCGA database (pro-jects TCGA-LUAD and TCGA-LUSC), HRAS mutations were found in 3/550 (0.55%) adenocarcinomas and 8/480 (1.67%) squamous cell carcinomas (data available online: https://portal.gdc.cancer.gov/ accessed on 14 April 2022). Here, HRAS is linked to adenocarcinoma.